Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J, Bianchi A, De Castro Silva I, Deshpande NU, Cao LL, Mehra S, Singh S, Rafie C, Sun X, Chen X, Dai X, Colaprico A, Sharma P, Dosch AR, Pillai A, Hosein PJ, Nagathihalli NS, Komanduri KV, Wilson JM, Ban Y, Merchant NB.
Datta J, et al. Among authors: sun x.
Oncogene. 2022 Jul;41(28):3640-3654. doi: 10.1038/s41388-022-02368-w. Epub 2022 Jun 14.
Oncogene. 2022.
PMID: 35701533